{"entity":{"id":"stx-1911","kind":"drug","name":"STX-1911","aka":[],"tldr":"STX-1911 is an experimental bispecific CyTAC with antibody-drug conjugate platform antibody from Solu Therapeutics, in preclinical development for prostate cancer.","summary":"STX-1911 is a bispecific CyTAC with antibody-drug conjugate platform antibody from Solu Therapeutics. A bispecific CyTAC targeting two tumour antigens highly expressed in prostate cancer, using the company's antibody-drug conjugate platform antibody. Its furthest stage is preclinical development, for prostate cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Discovery stage per pipeline page. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Solu Therapeutics: solutherapeutics.com","url":"https://solutherapeutics.com/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["solu-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"STX-1911","modality":"Bispecific CyTAC with antibody-drug conjugate platform antibody","mechanism":"A bispecific CyTAC targeting two tumour antigens highly expressed in prostate cancer, using the company's antibody-drug conjugate platform antibody.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/stx-1911/","neighbours":{"company":[{"id":"solu-therapeutics","kind":"company","name":"Solu Therapeutics","route":"/companies/solu-therapeutics/"}]}}